PT1200385E - Cristais do sal de sodio de pravastatina - Google Patents

Cristais do sal de sodio de pravastatina

Info

Publication number
PT1200385E
PT1200385E PT00946239T PT00946239T PT1200385E PT 1200385 E PT1200385 E PT 1200385E PT 00946239 T PT00946239 T PT 00946239T PT 00946239 T PT00946239 T PT 00946239T PT 1200385 E PT1200385 E PT 1200385E
Authority
PT
Portugal
Prior art keywords
sodium salt
pravastatin
crystalline form
cervastatin
fluvastatin
Prior art date
Application number
PT00946239T
Other languages
English (en)
Inventor
Zlatko Pflaum
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1200385(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of PT1200385E publication Critical patent/PT1200385E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT00946239T 1999-08-06 2000-08-04 Cristais do sal de sodio de pravastatina PT1200385E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9900191A SI20305A (sl) 1999-08-06 1999-08-06 Kristali natrijeve soli pravastatina

Publications (1)

Publication Number Publication Date
PT1200385E true PT1200385E (pt) 2005-04-29

Family

ID=20432515

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00946239T PT1200385E (pt) 1999-08-06 2000-08-04 Cristais do sal de sodio de pravastatina

Country Status (24)

Country Link
US (3) US7078558B1 (pt)
EP (1) EP1200385B2 (pt)
JP (1) JP2003506424A (pt)
KR (2) KR100766928B1 (pt)
CN (1) CN1205172C (pt)
AT (1) ATE287389T1 (pt)
BG (1) BG65368B1 (pt)
CA (1) CA2379335A1 (pt)
CZ (1) CZ2002414A3 (pt)
DE (1) DE60017568T2 (pt)
DK (1) DK1200385T3 (pt)
ES (1) ES2235911T5 (pt)
HR (1) HRP20020106A2 (pt)
HU (1) HUP0202536A3 (pt)
IL (3) IL148050A0 (pt)
NZ (1) NZ516685A (pt)
PL (1) PL365850A1 (pt)
PT (1) PT1200385E (pt)
RU (1) RU2247711C2 (pt)
SI (2) SI20305A (pt)
SK (1) SK1742002A3 (pt)
WO (1) WO2001010813A1 (pt)
YU (1) YU5402A (pt)
ZA (1) ZA200200437B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SK8312002A3 (en) 1999-12-14 2003-05-02 Biogal Gyogyszergyar Novel forms of pravastatin sodium
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
CZ2004943A3 (cs) * 2002-03-18 2005-02-16 Biocon Limited Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic
WO2004110585A1 (ja) * 2003-06-10 2004-12-23 Taisho Pharmaceutical Co., Ltd. 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤
CN1293874C (zh) * 2003-08-18 2007-01-10 李朝晖 以洛伐他汀盐为主要活性成分的中药红曲及其制剂
DE04811862T1 (de) 2003-11-24 2006-03-02 Teva Gyogyszergyar Reszvenytarsasag Verfahren zur Reinigung von Pravastatin
WO2005084669A1 (en) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Pharmaceutical composition
KR20070038553A (ko) 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
EP1833780A1 (en) * 2005-02-09 2007-09-19 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Methods of making pravastatin sodium
JP4895510B2 (ja) * 2005-02-23 2012-03-14 株式会社トクヤマ バリオールアミンの製造方法
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
US20110112053A1 (en) * 2008-04-16 2011-05-12 University Of Utah Research Foundation Pharmacological targeting of vascular malformations
CN101348476B (zh) * 2008-09-05 2011-05-11 丽珠集团新北江制药股份有限公司 一种制备4,5,6,7-四氢普伐他汀及其钠盐的方法和固体结晶形式
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
CN102533893A (zh) * 2010-12-09 2012-07-04 浙江海正药业股份有限公司 一种制备莫那可林j的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
US6098031A (en) 1998-03-05 2000-08-01 Gsi Lumonics, Inc. Versatile method and system for high speed, 3D imaging of microscopic targets
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
TR200600009T2 (tr) † 1999-02-03 2006-08-21 Institute For Drug Research Ltd. Pravastatinin hazırlanması için mikrobiyal işlem.@

Also Published As

Publication number Publication date
SI20305A (sl) 2001-02-28
ES2235911T5 (es) 2012-02-27
CA2379335A1 (en) 2001-02-15
ZA200200437B (en) 2003-03-26
BG106389A (en) 2002-09-30
EP1200385A1 (en) 2002-05-02
EP1200385B1 (en) 2005-01-19
DE60017568D1 (de) 2005-02-24
HUP0202536A3 (en) 2003-04-28
EP1200385B2 (en) 2011-09-21
ES2235911T3 (es) 2005-07-16
IL148050A (en) 2008-11-03
CN1205172C (zh) 2005-06-08
SI1200385T2 (sl) 2012-02-29
WO2001010813A1 (en) 2001-02-15
IL148050A0 (en) 2002-09-12
US20060183929A1 (en) 2006-08-17
ATE287389T1 (de) 2005-02-15
RU2247711C2 (ru) 2005-03-10
CZ2002414A3 (cs) 2002-07-17
US6740775B1 (en) 2004-05-25
PL365850A1 (en) 2005-01-10
HUP0202536A2 (hu) 2003-01-28
DK1200385T3 (da) 2005-05-23
CN1368948A (zh) 2002-09-11
IL187261A0 (en) 2008-02-09
US7078558B1 (en) 2006-07-18
KR20020025204A (ko) 2002-04-03
KR20070086847A (ko) 2007-08-27
KR100766928B1 (ko) 2007-10-17
JP2003506424A (ja) 2003-02-18
HRP20020106A2 (en) 2003-04-30
SI1200385T1 (en) 2005-08-31
SK1742002A3 (en) 2002-06-04
BG65368B1 (bg) 2008-04-30
NZ516685A (en) 2004-01-30
YU5402A (sh) 2005-03-15
DE60017568T2 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IL143759A0 (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS
IS2113B (is) Ný sölt HMG-CoA redúktasatálma
ATE260101T1 (de) Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
YU81800A (sh) POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
NZ535910A (en) Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying
ATE418979T2 (de) Stabilisiertes arzneimittel und arzneizubereitung
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže